MAY 30, 2018 12:00 PM PDT

High Throughput Screening Robotics within the UK Centre for Drug Discovery

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Director High Throughput Screening, AstraZeneca
      Mark Wigglesworth joined AstraZeneca in Sept 2012 to lead the newly formed Global High Throughput Screening Centre. His screening experience was gained at SmithKline Beecham and GlaxoSmithKline where he worked extensively in G-Protein coupled receptor (GPCR) drug discovery initiating and leading a number of projects to deliver lead molecules to drug discovery programmes. Mark has led groups of scientists responsible for delivery of structure activity relationship data to iterative chemistry programmes as well as working within Compound Management. Mark has worked collaboratively with several academic groups and organisations such as MRC-T, has contributed to numerous publications in the field of GPCR pharmacology and Compound Management including editing a book describing the Management of Biological and Chemical Samples for Screening Applications. In his current role he leads a team of more than 20 scientists dedicated to identifying novel chemical starting points for drug discovery programmes.


    AstraZeneca has an ambition to create a porous organisation, seamlessly collaborating with external partners. This desire has led to the establishment of the AstraZeneca-MRC UK Centre for Lead Discovery, ultimately located in the future R&D centre in Cambridge, UK. 

    This new global screening centre encompassing AstraZeneca, Medical Research Council, Cancer Research UK and additional scientific partners has created the unique opportunity to completely re-develop our screening infrastructure and its capabilities, resulting in the concept of our next generation of HTS automation to deliver the varied capacity and assays formats across this partnership. This presentation will describe the generation, use and support for this new generation of HTS screening. 

    Learning Objectives: 

    1. To understand the complexity of a High Throughput Screening laboratory
    2. How collaborations can drive further success

    Show Resources
    Loading Comments...